N-(3-(dimethylamino)propyl)methacrylamide (DMAPMA) is a cationic monomer that has been widely studied for its potential applications in various fields, including biomaterials, drug delivery, and gene therapy. It is a versatile monomer that can be easily polymerized via free radical polymerization, yielding polymers with tunable properties, such as biocompatibility, hydrophilicity, and degradability. The presence of the tertiary amine group in DMAPMA allows for the formation of polycations that can interact with negatively charged biomolecules, such as DNA and proteins, making it suitable for gene delivery applications. The polymer exhibits excellent biocompatibility, making it suitable for biomaterial applications. The study of DMAPMA and its polymers focuses on exploring its versatility for diverse applications and understanding its behavior in biological systems. For instance, research has explored its use in formulating hydrogels for tissue engineering, designing nanoparticles for drug delivery, and creating gene carriers for therapeutic applications.'
N-(3-(dimethylamino)propyl)methacrylamide: used to produce a surface suitable for growing embryonic stem cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 78882 |
| CHEBI ID | 189271 |
| SCHEMBL ID | 21954 |
| MeSH ID | M0587186 |
| Synonym |
|---|
| 2-propenamide, n-[3-(dimethylamino)propyl]-2-methyl- |
| ec 226-002-3 |
| unii-63obq7bzds |
| 63obq7bzds , |
| n-[3-(dimethylamino)propyl]methacrylamide, 99%, contains mehq as inhibitor |
| n-(3-(dimethylamino)propyl)methacrylamide |
| einecs 226-002-3 |
| 2-propenamide, n-(3-(dimethylamino)propyl)-2-methyl- |
| 5205-93-6 |
| n-[3-(dimethylamino)propyl]-2-methylprop-2-enamide |
| einecs 266-635-2 |
| dmapma |
| FT-0694966 |
| D1919 |
| n-(3-dimethylaminopropyl)methacrylamide |
| dimethylaminopropyl methacrylamide |
| CHEBI:189271 |
| 67296-21-3 |
| n-((dimethylamino)propyl)methacrylamide |
| NCGC00255635-01 |
| dtxcid5020154 |
| dtxsid7040154 , |
| cas-5205-93-6 |
| tox21_301671 |
| n-[3-(dimethylamino) propyl]methacrylamide |
| n-[3-(dimethylamino)propyl]methacrylamide |
| dimethylamino propyl methacrylamide |
| AKOS015903367 |
| n-(3-dimethylamonopropyl)-methacrylamide (dmapma) |
| dimethylaminopropyl methacrylamide [inci] |
| acrylamide, n-(3-(dimethylamino)propyl)-2-methyl- |
| n,n-dimethylaminopropyl methacrylamide |
| dimethyl(3-(methacryloylamino)propyl)amine |
| mhoromer bm 611 |
| n-(3-(n,n-dimethylamino)propyl)methacrylamide |
| SCHEMBL21954 |
| n-(3-dimethylamino-propyl)-2-methyl-acrylamide |
| acrylamide, n-[3-(dimethylamino)propyl]-2-methyl- |
| 2-propenamide, n-[(dimethylamino)propyl]-2-methyl- |
| dimethylaminopropyl methacrylamide (dmapma) |
| mfcd00038359 |
| n-(3-dimethylaminopropyl)methacrylamide (stabilized with mehq) |
| n-(3-dimethylaminopropyl)methacrylamide, (stabilized with mehq) |
| dmapma, 99% |
| dimethyl amino propyl methacrylamide |
| DS-3823 |
| Q27263632 |
| SY052113 |
| A871085 |
| dimethylaminopropyl methacrylamide (dmapma); n-[3-(dimethylamino)propyl]methacrylamide; dmapma; dimethylaminopropyl methacrylamide |
| CS-W017689 |
| dmapma compound |
| Class | Description |
|---|---|
| tertiary amino compound | A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.45) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||